Xenon Pharmaceuticals reported that azetukalner, a Kv7 potassium channel opener, met its primary endpoint in the Phase III X‑TOLE2 study for focal onset seizures with a large, placebo‑adjusted reduction in seizure frequency. The result exceeded expectations and management said it will pursue an NDA later this year. The readout revives interest in the Kv7 target after years of setbacks and positions azetukalner as a once‑daily oral alternative in focal epilepsy. Market reaction was immediate, with a sharp share rally; analysts highlighted the combination of robust efficacy and an oral dosing profile as drivers for rapid regulatory planning.